Advances in stroke care and research in 2010

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 9, 2011, Pages 562-569

  Wang, Chun Juan ^a   Wang, Chun Xue ^a   Zhang, Liqun ^b   Wang, Yi Long ^a   Wang, Yong Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Advances; Management; Prevention; Rehabilitation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; NICARDIPINE; PLACEBO;

ANEURYSM; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAROTID ANGIOPLASTY; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; EXTRAVASATION; FIBRIN CLOT; FIBRINOLYTIC THERAPY; GENOME; HEMATOMA; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MEDICAL RESEARCH; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREDICTIVE VALUE; QUALITY CONTROL; REVIEW; ROBOTICS; STROKE; SUBARACHNOID HEMORRHAGE;

ANIMALS; CLINICAL TRIALS AS TOPIC; GUIDELINES AS TOPIC; HUMANS; RISK FACTORS; STROKE;

EID: 80052078033     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05566.x     Document Type: Review

References (47)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995; 333: 1581-7.
2. Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
3. Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-51.
4. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31: 811-6.
5. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3-5hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-26.
6. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
7. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3-4.5hours after acute ischemic stroke. N. Engl. J. Med. 2008; 359: 1317-29.
8. Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
9. Davis SM, Donnan GA, Parsons MW et al. Effects of alteplase beyond 3h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol. 2008; 7: 299-309.
10. Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch. Neurol. 1998; 55: 1475-82.
11. Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J. Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature 2010; 465: 478-82.
12. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 2007; 27: 697-709.
13. del Zoppo GJ, Hawkins BT. Throwing out the thromboemboli. N. Engl. J. Med. 2010; 363: 1282-4.
14. Brott T, Broderick J, Kothari R et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1-5.
15. Leira R, Davalos A, Silva Y et al. Early neurologic deterioration in intracerebral hemorrhage: Predictors and associated factors. Neurology 2004; 63: 461-7.
16. Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: Relationship between elevated blood pressure and hematoma enlargement. Stroke 2004; 35: 1364-7.
17. Lim JK, Hwang HS, Cho BM et al. Multivariate analysis of risk factors of hematoma expansion in spontaneous intracerebral hemorrhage. Surg. Neurol. 2008; 69: 40-5.
18. Antihypertensive Treatment of Acute Cerebral Haemorrhage (ATACH) Investigators. Antihypertensive treatment of acute cerebral hemorrhage. Crit. Care Med. 2010; 38: 637-48.
19. Anderson CS, Huang Y, Arima H et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010; 41: 307-12.
20. Arima H, Anderson CS, Wang JG et al. Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage. Hypertension 2010; 56: 852-8.
21. Yasuno K, Bilguvar K, Bijlenga P et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat. Genet. 2010; 42: 420-5.
22. Bilguvar K, Yasuno K, Niemela M et al. Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat. Genet. 2008; 40: 1472-7.
23. Ong KT, Perdu J, De Backer J et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: A prospective randomised, open, blinded-endpoints trial. Lancet 2010; 376: 1476-84.
24. Murphy AJ, Woollard KJ. High-density lipoprotein. A potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol. 2010; 37: 710-8.
25. Podrez EA. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol. 2010; 37: 719-25.
26. Pocathikorn A, Taylor RR, Mamotte CD. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells. Clin. Exp. Pharmacol. Physiol. 2010; 37: 471-6.
27. Brott TG, Hobson RW II, Howard G et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 2010; 363: 11-23.
28. Bonati LH, Dobson J, Algra A et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: A preplanned meta-analysis of individual patient data. Lancet 2010; 376: 1062-73.
29. Furie KL, Kasner SE, Adams RJ et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-76.
30. Mas JL, Chatellier G, Beyssen B et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N. Engl. J. Med. 2006; 355: 1660-71.
31. Ringleb PA, Allenberg J, Bruckmann H et al. 30day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: A randomised non-inferiority trial. Lancet 2006; 368: 1239-47.
32. Bonati LH, Jongen LM, Haller S et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: A substudy of the International Carotid Stenting Study (ICSS). Lancet Neurol. 2010; 9: 353-62.
33. Reiff T, Stingele R, Eckstein HH et al. Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. Endarterectomy: SPACE2. A three-arm randomised-controlled clinical trial. Int. J. Stroke 2009; 4: 294-9.
34. Yadav JS, Wholey MH, Kuntz RE et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. 2004; 351: 1493-501.
35. O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-23.
36. Dittrich R, Ritter MA, Kaps M et al. The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: Signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial. Stroke 2006; 37: 1065-9.
37. Wong KS, Chen C, Fu J et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): A randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010; 9: 489-97.
38. Markus HS, King A, Shipley M et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): A prospective observational study. Lancet Neurol. 2010; 9: 663-71.
39. Sattelmair JR, Kurth T, Buring JE, Lee IM. Physical activity and risk of stroke in women. Stroke 2010; 41: 1243-50.
40. Lo AC, Guarino PD, Richards LG et al. Robot-assisted therapy for long-term upper-limb impairment after stroke. N. Engl. J. Med. 2010; 362: 1772-83.
41. Fonarow GC, Reeves MJ, Smith EE et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. Circ. Cardiovasc. Qual. Outcomes 2010; 3: 291-302.
42. Reeves MJ, Parker C, Fonarow GC, Smith EE, Schwamm LH. Development of stroke performance measures: Definitions, methods, and current measures. Stroke 2010; 41: 1573-8.
43. Hsieh FI, Lien LM, Chen ST et al. Get With the Guidelines-Stroke performance indicators. Surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation 2010; 122: 1116-23.
44. Schwamm LH, Reeves MJ, Pan W et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010; 121: 1492-501.
45. Menon BK, Frankel MR, Liang L et al. Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. Stroke 2010; 41: 2094-7.
46. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
47. Smith EE, Shobha N, Dai D et al. Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. Circulation 2010; 122: 1496-504.